EYPT Q4 2025 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$620,000-94.6% YoY

Gross Profit

$245,00039.5% margin

Operating Income

-$70M-11346.0% margin

Net Income

-$68M-10904.7% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

-35.8%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$66M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$364M

Total Liabilities

$58M

Stockholders' Equity

$306M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$620,000	$12M	-94.6%
Gross Profit	$245,000	$11M	-97.7%
Operating Income	-$70M	-$45M	-55.5%
Net Income	-$68M	-$41M	-63.3%